HPLC + MS
Independently tested for identity and purity
NP-RETA-02
Aug 6, 2026
99.23%
View Certificate of Analysis
CAS# 2381089-83-2
Also Known As LY3437943
Class Synthetic Peptide
Form Lyophilized Powder
Receptor Target
Receptor Target
Receptor Target
Retatrutide (LY3437943, CAS# 2381089-83-2) is a synthetic peptide compound classified as a triple receptor agonist with binding activity at the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR). Supplied by NexPept as a lyophilized powder for in vitro laboratory research use. This compound has not been authorized by Health Canada for any therapeutic, clinical, or human use.
CAS#, formula, molecular weight, analytical data
| Property | Value |
|---|---|
| CAS Number | 2381089-83-2 |
| Research Designation | LY3437943 |
| Compound Class | Synthetic incretin-based peptide — triple receptor agonist |
| Receptor Targets | GLP-1R, GIPR, GcgR |
| Physical Form | Lyophilized powder |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + Mass Spectrometry (MS) |
| Appearance | White to off-white lyophilized solid |
Receptor pharmacology — laboratory use only
Glucagon-like peptide-1 receptor — incretin signalling pathway
Glucose-dependent insulinotropic polypeptide receptor
Glucagon receptor — hepatic and metabolic signalling research
Retatrutide is studied in preclinical in vitro settings as a pharmacological tool for investigating simultaneous multi-receptor agonism across the incretin signalling system. Research applications include receptor binding assays, competitive displacement studies, and in vitro signalling cascade analysis. As an investigational compound with defined receptor selectivity, it is used in controlled laboratory environments to study receptor pharmacology and downstream signalling mechanisms.
Research context: Retatrutide is an investigational compound studied in scientific research involving GLP-1R, GIPR, and GcgR signalling pathways. Research into this compound remains ongoing. It has not been authorized by Health Canada for human or veterinary use.
10mg · 20mg · 50mg — lyophilized powder
| Format | Net Quantity | Physical Form |
|---|---|---|
| Retatrutide 10mg | 10 mg / vial | Lyophilized powder |
| Retatrutide 20mg | 20 mg / vial | Lyophilized powder |
| Retatrutide 50mg | 50 mg / vial | Lyophilized powder |
All formats are sourced from the same verified batch. Selection should be based on the quantity required for your specific in vitro research protocol as determined by qualified research personnel.
Controlled storage conditions for lyophilized material
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture. Handling conditions should be established by qualified research personnel in accordance with the specific experimental protocol.
Note: No preparation, reconstitution, or administration instructions are provided. This compound is supplied for in vitro laboratory research use only. All handling must be conducted by qualified personnel following institutional safety protocols.
Scientific references & related resources
PubMed — LY3437943 / Retatrutide — peer-reviewed scientific literature on this compound
Retatrutide Canada — NexPept compound overview and in vitro research context
Research Peptides in Canada — sourcing and research context for Canadian laboratories
What Are Research Peptides? — peptide classification and in vitro research context
This material must not be administered to humans or animals. No dosage, preparation, reconstitution, or administration instructions are provided or implied. All handling and use must be conducted by qualified personnel in accordance with applicable institutional policies and legal requirements.
| Quantity | 2 vials, 5 vials, 10 vials |
|---|
Be the first to review “Retatrutide 10mg”
Related products
Reviews
There are no reviews yet.